Bristol Myers Squibb Company $BMY Stock Position Lifted by Burney Co.

Burney Co. grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 507.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 63,621 shares of the biopharmaceutical company’s stock after acquiring an additional 53,141 shares during the quarter. Burney Co.’s holdings in Bristol Myers Squibb were worth $3,432,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Bristol Myers Squibb by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 195,984,009 shares of the biopharmaceutical company’s stock valued at $8,838,879,000 after acquiring an additional 1,058,803 shares in the last quarter. State Street Corp raised its holdings in shares of Bristol Myers Squibb by 2.0% during the third quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock worth $4,356,445,000 after purchasing an additional 1,855,238 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Bristol Myers Squibb by 11.5% during the third quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company’s stock worth $818,105,000 after purchasing an additional 1,873,618 shares during the period. Legal & General Group Plc raised its holdings in shares of Bristol Myers Squibb by 8.4% during the third quarter. Legal & General Group Plc now owns 17,075,743 shares of the biopharmaceutical company’s stock worth $770,116,000 after purchasing an additional 1,317,199 shares during the period. Finally, Pzena Investment Management LLC raised its holdings in shares of Bristol Myers Squibb by 0.4% during the third quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company’s stock worth $672,062,000 after purchasing an additional 58,129 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Cobenfy showing commercial momentum — grew to roughly $155M in 2025 and is outpacing peers, supporting upside potential from new indications. Does Cobenfy Have the Potential to Become a Top Drug for BMY?
• Positive Sentiment: New R&D collaboration with Oxford BioTherapeutics to discover next‑generation T‑cell engagers for solid tumors — expands BMS’s oncology pipeline and validates external discovery partnerships. Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb…
• Positive Sentiment: Analyst support: Guggenheim reiterated a Buy rating, which can lend short-term confidence to the stock. Guggenheim Reiterates Buy Rating for Bristol Myers Squibb (NYSE:BMY)
• Neutral Sentiment: Dividend resilience noted — BMY highlighted as a recession‑resistant dividend stock, supporting income‑investor interest. 2 Recession Resistant Dividend Stocks to Buy Now While They’re Still Cheap
• Neutral Sentiment: Cantor Fitzgerald adjusted its price recommendation history (raised prior levels) but flagged Q1 catalysts are weak—mixed messaging that tempers conviction. Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst
• Neutral Sentiment: Macro note: BofA says many biopharma names are largely exempt from proposed pharma tariffs — a mild tailwind for the sector. Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says
• Negative Sentiment: Near‑term revenue/earnings caution: a Zacks piece notes BMY’s YTD gains but warns generic erosion and the company’s 2026 sales outlook are reasons for investor caution. BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
• Negative Sentiment: Earnings risk: previews and analyst commentary expect a sizable Q1 earnings decline, which increases short‑term downside risk around the upcoming release. Bristol-Myers Squibb Earnings Preview: What to Expect
• Negative Sentiment: Some sell‑side adjustments show modestly lower price targets (Bank of America trimmed a target from $68 to $67; other outlets note PT shifts), signaling cautious near‑term sentiment. Benzinga

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research reports. HSBC increased their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Scotiabank reissued a “sector perform” rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Citigroup increased their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Morgan Stanley reissued an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. Finally, Cantor Fitzgerald increased their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a report on Wednesday, April 8th. Nine equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $61.71.

Bristol Myers Squibb Stock Down 0.0%

BMY stock opened at $58.61 on Monday. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm’s 50-day simple moving average is $59.78 and its 200 day simple moving average is $53.24. The stock has a market cap of $119.66 billion, a PE ratio of 16.99, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period last year, the business earned $1.67 EPS. The firm’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.09% of the stock is currently owned by company insiders.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.